Results 241 to 250 of about 120,744 (362)
Real-world retrospective cohort study evaluating the tolerability of immune globulin intravenous 10% (BIVIGAM<sup>®</sup>). [PDF]
Van Anglen LJ +3 more
europepmc +1 more source
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao +13 more
wiley +1 more source
In Yoo and Mainkar et al., we present a minimally invasive, CM‐selective modRNA delivery system encapsulated in lipid nanoparticles for intravenous (IV) administration. This platform enables selective cardiac translation of therapeutic modRNA but suppresses expression in off‐target tissues, including tumors.
Jimeen Yoo +19 more
wiley +1 more source
Scars exhibit vascular abnormal alterations, including upregulated NRP1 expression in endothelial cells, increased vascular density and branching, compromised vessel wall integrity, and incomplete pericyte coverage. Therapeutic targeting of NRP1 through hydrogel spray delivery offers a promising approach to normalize aberrant vasculature and prevent ...
Yu Wang +11 more
wiley +1 more source
Intra-articular antibiotic infusions versus intravenous antibiotic administration for infected knee arthroplasty: a study protocol for a randomized multicenter clinical trial. [PDF]
Ji B +20 more
europepmc +1 more source
PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang +13 more
wiley +1 more source

